{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:24:20Z","timestamp":1787261060288,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K23HL151671"],"award-info":[{"award-number":["K23HL151671"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.chest.2026.01.031","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:52:59Z","timestamp":1773676379000},"page":"169-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can Posttransplant Cyclophosphamide Reduce Bronchiolitis Obliterans Syndrome Risk Through Chronic Graft vs Host Disease Prevention?"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-5021","authenticated-orcid":false,"given":"Reid H.","family":"Eggleston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hefazi Torghabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemang","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chest.2026.01.031_bib1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.chest.2026.01.031_bib2","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood.V74.4.1428.1428","article-title":"Predictors of death from chronic graft-versus-host disease after bone marrow transplantation","volume":"74","author":"Wingard","year":"1989","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.chest.2026.01.031_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.bbmt.2007.05.001","article-title":"Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Yoshihara","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.chest.2026.01.031_bib4","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41409-024-02422-z","article-title":"Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens","volume":"59","author":"Duque-Afonso","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.chest.2026.01.031_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1378\/chest.128.1.153","article-title":"Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia","volume":"128","author":"Santo Tomas","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.chest.2026.01.031_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106286","article-title":"Updated prevalence, predictors and treatment outcomes for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation","volume":"177","author":"Pham","year":"2021","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2026.01.031_bib7","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/bmt.2013.17","article-title":"Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight\u2014new perspectives?","volume":"48","author":"Ditschkowski","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.chest.2026.01.031_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2011.10.005","article-title":"Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment","volume":"49","author":"Bacigalupo","year":"2012","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.chest.2026.01.031_bib9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2009.1018","article-title":"Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation","volume":"302","author":"Williams","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.chest.2026.01.031_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12185-011-0809-8","article-title":"Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation","volume":"93","author":"Nakaseko","year":"2011","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.chest.2026.01.031_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"93","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.chest.2026.01.031_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.07.021","article-title":"Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.chest.2026.01.031_bib13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/ejh.14294","volume":"113","author":"Redondo","year":"2024","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.chest.2026.01.031_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtct.2022.07.013","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume":"28","author":"Saliba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.chest.2026.01.031_bib15","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1016\/j.chest.2026.01.031_bib16","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2026.01.031_bib17","doi-asserted-by":"crossref","first-page":"204.e201","DOI":"10.1016\/j.jtct.2022.12.001","article-title":"Risk factors for bronchiolitis obliterans syndrome after initial detection of pulmonary impairment after hematopoietic cell transplantation","volume":"29","author":"Alkhunaizi","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.chest.2026.01.031_bib18","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.chest.2026.01.031_bib19","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1182\/bloodadvances.2023009791","article-title":"Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD","volume":"7","author":"Maurer","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.chest.2026.01.031_bib20","doi-asserted-by":"crossref","first-page":"327.e321","DOI":"10.1016\/j.jtct.2023.02.001","article-title":"A calcineurin inhibitor free graft versus host disease prophylaxis for patients undergoing matched related and matched unrelated donor allogeneic hematopoietic cell transplant","volume":"29","author":"Iqbal","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6 pt 1","key":"10.1016\/j.chest.2026.01.031_bib21","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1164\/ajrccm.154.6.8970380","article-title":"Lung toxicity associated with cyclophosphamide use. Two distinct patterns","volume":"154","author":"Malik","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2026.01.031_bib22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation","volume":"22","author":"Williams","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.chest.2026.01.031_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.transci.2004.02.003","article-title":"Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease","volume":"30","author":"Ilhan","year":"2004","journal-title":"Transfus Apher Sci"},{"issue":"12","key":"10.1016\/j.chest.2026.01.031_bib24","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/sj.bmt.1704984","article-title":"Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors","volume":"35","author":"Foss","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.chest.2026.01.031_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1183\/23120541.00185-2022","article-title":"Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions","volume":"8","author":"Glanville","year":"2022","journal-title":"ERJ Open Res"},{"issue":"9","key":"10.1016\/j.chest.2026.01.031_bib26","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41409-022-01725-3","article-title":"Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"57","author":"Lazzari","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"33","key":"10.1016\/j.chest.2026.01.031_bib27","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO-25-01238","article-title":"Sirolimus and cyclosporine with post-transplant cyclophosphamide or mycophenolate mofetil as graft-versus-host disease prophylaxis in unrelated donor hematopoietic cell transplantation","volume":"43","author":"Ueda Oshima","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226003065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226003065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:30:54Z","timestamp":1787257854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226003065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0012369226003065"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.01.031","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can Posttransplant Cyclophosphamide Reduce Bronchiolitis Obliterans Syndrome Risk Through Chronic Graft vs Host Disease Prevention?","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}